RecruitingNCT04736381
Impact of the Microbiota on the Likelihood of Renal Graft Rejection
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Enrollment
70 participants
Start Date
Oct 7, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Identification of a bacterial signature in the blood or stool that may be associated with acute rejection in patients treated with Nulojix during their first year of transplant.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- Patients called for a kidney transplant
- Induction therapy with Simulect, maintenance therapy with Nulojix, mycophenolate acid and steroids
- Patient having signed the informed consent
Exclusion Criteria6
- Multiple grafts combined or sequential
- Induction therapy with polyclonal antibodies
- HIV or active viral infection such as hepatitis B or C
- Active bacterial infection
- Pregnancy or breastfeeding at time of inclusion
- Patient unable to express their consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBelatacept Injection [Nulojix]
Drugs administrated are part of the usual care
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04736381
Related Trials
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT0741247010 locations
Trifecta-Kidney cfDNA-MMDx Study
NCT0423970331 locations
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
NCT074158761 location
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
NCT070065321 location
Platelet Aggregation in the Diagnosis of Acute Graft Rejection
NCT072755411 location